Skip to main content

Latent viruses in human genome

Latent viruses in human genome inspire novel directions for kidney cancer immunotherapy


Dana-Farber investigators found that normally defunct viral genes that lie dormant in the human genome can be activated in the most common form of kidney cancer (clear cell renal cell carcinoma) and can end up triggering an immune response against the cancer. The human genome contains viral DNA that was integrated into the genomic code long ago. A subset of these viral genes can still be reactivated under certain circumstances to produce viral proteins.

Published in Cell, this study showed that when the tumor suppressor gene VHL is inactivated by a mutation—a hallmark of clear cell renal cell cancer cells—these viruses in our genome (called endogenous retroviruses) are more likely to produce their proteins and that this process is driven by a human protein called HIF2, which is overabundant when VHL is crippled.

The team also found that the cancer cells break these viral proteins into fragments and present them on the cell surface as flags that have the potential to stimulate an immune response. Additional tests in human samples and in mice suggest that these flags can be detected by the immune cells called T cells and do stimulate an immune response against the cancer.

Evidence suggests that kidney cancer, unlike most other forms of cancer, is sometimes eradicated by the immune system. Exactly how is not well understood. This study suggests that the immune system can mount an attack on cancer cells that, due to the presence of cancer-driving mutations, present fragments of endogenous retroviral proteins on their surface. The discovery points to the potential for investigating new ways to leverage endogenous retroviruses in the development of novel immunotherapies.

Kidney cancer, renal cell carcinoma, tumor growth, nephrectomy, targeted therapy, immunotherapy, metastatic kidney cancer, oncogenes, tumor microenvironment, angiogenesis, renal biopsy, VEGF inhibitors, checkpoint inhibitors, genetic mutations, risk factors, early detection, survival rates, kidney cancer symptoms, renal oncology, clinical trials

#KidneyCancer, #RenalCellCarcinoma, #TumorGrowth, #Nephrectomy, #TargetedTherapy, #Immunotherapy, #MetastaticCancer, #Oncogenes, #TumorMicroenvironment, #Angiogenesis, #RenalBiopsy, #VEGFinhibitors, #CheckpointInhibitors, #GeneticMutations, #CancerRiskFactors, #EarlyDetection, #SurvivalRates, #CancerSymptoms, #RenalOncology, #ClinicalTrials

Comments

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...

Genetics study on COVID-19

Large genetic study on severe COVID-19 Bonn researchers confirm three other genes for increased risk in addition to the known TLR7 gene Whether or not a person becomes seriously ill with COVID-19 depends, among other things, on genetic factors. With this in mind, researchers from the University Hospital Bonn (UKB) and the University of Bonn, in cooperation with other research teams from Germany, the Netherlands, Spain and Italy, investigated a particularly large group of affected individuals. They confirmed the central and already known role of the TLR7 gene in severe courses of the disease in men, but were also able to find evidence for a contribution of the gene in women. In addition, they were able to show that genetic changes in three other genes of the innate immune system contribute to severe COVID-19. The results have now been published in the journal " Human Genetics and Genomics Advances ". Even though the number of severe cases following infection with the SARS-CoV-...